214 related articles for article (PubMed ID: 6580948)
1. Phase II study of amsacrine gluconate in refractory leukemia.
Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
[TBL] [Abstract][Full Text] [Related]
2. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
3. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
4. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
5. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Miller LP; Miller DR; Tan CT
Cancer Treat Rep; 1983 May; 67(5):439-43. PubMed ID: 6189604
[No Abstract] [Full Text] [Related]
7. AMSA--a promising new agent in refractory acute leukemia.
Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
[TBL] [Abstract][Full Text] [Related]
8. Trial of AMSA in acute leukemia.
Dupont JC; Garay GE; Scaghone C; Pavlovsky S; Woodley PV
Cancer Treat Rep; 1982 Jul; 66(7):1596-7. PubMed ID: 7046933
[No Abstract] [Full Text] [Related]
9. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
Vogler WR; Preisler HD; Winton EF; Gottlieb AJ; Goldberg J; Brennan J; Grunwald H; Rai K; Browman G; Miller KB
Cancer Treat Rep; 1986 Apr; 70(4):455-9. PubMed ID: 3516395
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
11. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
12. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
13. Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase II study.
Amrein PC; Coleman M; Richards F; Bhardwaj S; Kennedy BJ; Haurani FI; Frelick RW; Pastmantier MW; Herschkopf R
Cancer Treat Rep; 1984 Nov; 68(11):1397-8. PubMed ID: 6548660
[No Abstract] [Full Text] [Related]
14. Use of amsacrine in patients with acute leukemia at first relapse.
Danova M; Riccardi A; Invernizzi R; Ucci G; Girino M; Montecucco CM; Cresci R; Ascari E; Mauri C
Haematologica; 1985; 70(6):545-6. PubMed ID: 3938435
[No Abstract] [Full Text] [Related]
15. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
16. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
Amrein PC; Richards F; Coleman M; Poulin RF; Holland JF; Weinberg V; Perry M
Cancer Treat Rep; 1984 Jun; 68(6):923-4. PubMed ID: 6329510
[No Abstract] [Full Text] [Related]
18. [Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].
Cavalli F; Ryssel HJ; Batz K; Sonntag RW; Brunner KW
Schweiz Med Wochenschr; 1975 Feb; 105(8):250-3. PubMed ID: 1054886
[TBL] [Abstract][Full Text] [Related]
19. A phase I and II study of m-AMSA in acute leukaemia.
Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
[TBL] [Abstract][Full Text] [Related]
20. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Estey EH; Keating MJ; Smith TL; McCredie KB; Legha SS; Walters RS; Bodey GP; Freireich EJ
J Clin Oncol; 1984 Feb; 2(2):102-6. PubMed ID: 6583328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
